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Abstract
Background and Aims: Histological remission [HR] is a potential treatment target in ulcerative 
colitis [UC]. Limited ‘real world’ data are available on the reliability of histological scoring when 
assessing minimal histological inflammation. The aim of this study was to investigate the reliability 
of UC histological scores in colonic biopsies showing mucosal healing [MH] and limited histological 
inflammation, and to compare the ‘daily practice’ histological assessment with expert reviews by 
gastrointestinal [GI] pathologists.
Methods: We performed a retrospective single-centre study. Colonic biopsies from UC patients 
with MH [Mayo score ≤ 1] were included. All biopsies assessed in daily practice were reassessed 
by three blinded GI pathologists using three histological scores (Geboes score [GS], Riley score 
[RS], Harpaz [Gupta] Index [HGI]) and a global visual scale [GVS]. We evaluated inter- and intra-
observer variation between GI pathologists and correlations between scores including the initial 
histological assessment using Cronbach’s alpha and Spearman rho analysis.
Results: In total, 270 biopsies from 39 UC patients were included. The inter-observer concordance 
for all histological indexes was substantial to almost perfect [GS 0.84; HGI 0.61; GVS 0.74, RS 0.91]. 
Correlation between the RS and GS was almost perfect [R = 0.86], but we found no correlation 
between the primary histological assessment and reassessment by GI pathologists.
Conclusions: Current UC histological scores reliably assess limited histological inflammation in 
UC patients. The discrepancy between the initial histological assessment and the reassessment 
by dedicated GI pathologists suggests a gap between daily practice and academic expertise. This 
issue may limit the implementation of HR as a treatment target for UC in daily practice.
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1. Introduction
Treatment goals for inflammatory bowel disease [IBD] have changed 
from assessing primarily symptom-based treatment to evaluating 
treatment targets that combine both patient-reported outcome [PRO] 
remission and endoscopic remission (mucosal healing [MH]).1 The 
advent of biologicals with positive effects on mucosal inflammation 
has contributed significantly to this shift.2–6 MH is a well-accepted 
treatment target in clinical IBD trials7–10 and is associated with rele-
vant clinical outcomes.6,11–13 Some clinical trials have introduced even 
more stringent treatment targets in IBD such as ‘histological remission 
[HR]’. HR might be a better predictor of a more favourable disease 
course, in particular in ulcerative colitis [UC].14–18 However, there is 
no unified definition of HR,15,19,20 which seems pivotal for the design 
and comparability of clinical trials, but also for the use of HR as a 
treatment target in daily practice. Several scoring indexes are avail-
able to measure histological activity in UC. Frequently used scores 
include the Geboes score [GS], Riley score [RS] and to a lesser extent 
the easy to use Harpaz [Gupta] Index [HGI]. Only limited data on the 
reproducibility of these scores were available until recently.21–23 Two 
studies evaluating the reproducibility and reliability of these histo-
logical activity indexes showed a strong correlation between scores 
and good intra-observer reproducibility with moderate to good inter-
observer agreement.24,25 The greater portion of patients in both stud-
ies, however, had [mildly] active disease. Indeed, the histological item 
that showed the strongest intra- and inter-observer agreement was 
‘erosion/ulceration’, a feature that correlates with active disease. In 
addition, the assessing pathologists were all expert gastrointestinal 
[GI] pathologists. This leads us to two questions. First, does this high 
observer agreement still hold when re-evaluating colonic biopsies 
with MH that were initially assessed by a general pathologist as ‘HR’. 
Secondly, do these histological indexes, so far mainly used in clinical 
trials, correlate with the histological assessment in daily practice by a 
general pathologist? To assess these questions, we designed a study to 
compare the reproducibility and reliability of three histological scor-
ing indexes [GS, RS, HGI] and one global visual score [GVS] through 
intra- and inter-observer agreement testing, in colonic biopsies with 
MH that were primarily assessed as HR in daily practice. We also 
investigated the correlation between histological assessment of UC 
biopsies in daily practice and the re-assessment by specialized GI 
pathologists.
2. Materials and Methods
2.1. Study design
We designed a retrospective single-centre study in a tertiary referral 
centre. This trial [ISRCTN61139227] was approved by the Ethics 
Committee of Radboud University Medical Centre, Nijmegen, the 
Netherlands.
2.2. Patients
We searched our endoscopy database to identify patients with estab-
lished UC who met the inclusion criteria. Patients were included if they 
had [i] a colonoscopic examination between January 2014 and July 
2015, [ii] a well-established diagnosis of UC according to clinical and 
histological criteria [Montreal classification E1–3 were included26], 
[iii] endoscopic MH throughout the examined colon according to the 
Mayo endoscopic score ≤113,27,28 – after inclusion, two groups were 
distinguished based on the endoscopic Mayo score [0 vs 1] and [iv] 
obtained and well-documented colonic biopsies from rectum, sig-
moid and proximal colon [proximal of splenic flexure]. Patients were 
excluded if they had [i] a Mayo endoscopic score >1 or [ii] a diagnosis 
of either Crohn’s disease or IBD unclassified. Demographic data of 
patients were anonymously collected from digital patient records.
2.3. Assessment of biopsy specimens
Biopsies were paraffin-embedded, sectioned and H&E-stained. The 
slides were scanned at 200× magnification. All biopsies were reassessed 
by two blinded expert GI pathologists [IN, CB] and one GI pathology 
fellow [AT]. Two pathologists are employed in an academic hospital 
[IN, AT] and one in a large non-academic teaching hospital [CB]. Prior 
to the assessment a consensus meeting was held and teaching materials 
with sample images of the different scores were developed. Three histo-
logical scoring systems [GS, RS and HGI] were used during reassess-
ment, as well as a GVS, indicating a ‘first glance’ assessment. The GVS 
is a visual scale ranging from 0 [no activity] to 10 [maximal activity]. 
All three scoring systems are described in detail in Supplementary Data 
Tables S1–S3. The GS21 assesses five features which result in a score 
ranging from 0 to 5.4, with higher scores indicating more inflamma-
tion. The original RS evaluates six features which are scored on a four-
point scale [none, mild, moderate or severe], in which equal weight 
to all six measures was given.22 The HGI23 is based on three features 
resulting in a four-point scale [Histological Activity Index 0 to 3] with 
higher scores indicating greater inflammation.
Each pathologist scored all biopsies by sections that represent a 
specific part of the colon [rectum, left-sided or proximal of splenic 
flexure]. Each section contained several biopsies, with the worst score 
applied for further analysis. Two blinded pathologists [IN, AT] scored 
18 random sections twice, with an interval of at least 2 weeks, to 
evaluate intra-observer reliability. From all biopsies obtained during 
colonoscopy, the report of the ‘general pathologist [gp]’ [the general 
pathologist who initially assessed the biopsies in daily clinical set-
ting] was evaluated and used as a baseline to construct two groups 
for analysis. Biopsies that were initially evaluated as ‘histological 
remission’ [gpHR] were compared with those showing ‘histological 
inflammation’ [gpHI], with regard to inter-observer agreement and 
intra-observer reliability for all scores. In addition, we assessed the 
correlation between the primary histological assessment and the dif-
ferent histological scores as well as the correlation between endo-
scopic Mayo score and histological scores. Biopsies were divided and 
compared by location [rectum, left-sided colon, colon proximal of 
splenic flexure] and Montreal classification [E1–3].
2.4. Statistical analysis
SPSS version 22.0 and Scilab were used for the statistical analysis. 
We used descriptive statistics to analyse the results using counts and 
proportions for categorical data and means and standard deviations 
for continuous variables. We evaluated inter- and intra-observer vari-
ation of GI pathology experts for GS, HGI and GVS total scores in 
biopsies taken from endoscopically healed mucosa with Cronbach’s 
alpha statistics, and for the 95% confidence interval we used boot-
strapping and provided the percentage of agreement. We used the 
interpretation of kappa values as suggested by Landis29: 0.00 poor; 
0.00–0.20 slight; 0.21–0.40 fair; 0.41–0.60 moderate; 0.61–0.80 
substantial; 0.81–1.00 almost perfect. For the RS we evaluated inter- 
and intra-observer concordance between the six different items of 
the RS with Cronbach’s alpha statistics. Where there was almost 
perfect inter-observer concordance, we provide the percentage of 
agreement, because Cronbach’s alpha statistics could not reliable be 
used. The relationship between indexes was studied by Spearman’s 
correlation coefficient. We compared the outcome of biopsies that 
are primarily assessed as ‘normal’ [gpHR] or ‘abnormal’ [gpHI] by 
the general pathologist, and GI pathology experts.
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3. Results
3.1. General
We assessed 77 sections with 270 H&E-stained biopsies (143 rectum 
[53%], 20 sigmoid [7%], 107 proximal of splenic flexure [40%]) 
from 43 endoscopies [39 colonoscopies, four sigmoidoscopies] in 39 
patients. The median number of biopsies was 4.61 in the rectum and 
3.34 in the proximal colon. Sixty-three sections [82%] were initially 
assessed by the general pathologist as histologically healed [gpHR]. 
Demographic variables of the included patients and details on en-
doscopy are summarized in Table 1.
3.2. Endoscopic Mayo score – histological 
activity scores
In 82% [32/39] of the colonoscopies we found an endoscopy score of 
Mayo 0 in the entire colon, with 100% of patients [39/39] showing 
Mayo 0 in the colon proximal of the splenic flexure. In 33/43 endos-
copies we found a Mayo score of 0 in the rectosigmoid [76.7%]. 
Eighty-seven per cent [67/77] of all evaluated sections were biopsy 
sections taken from areas in the colon classified as endoscopy score 
Mayo 0, with 13% [10/77] scored as Mayo 1.
3.3. Endoscopy and histology scores – general 
pathologist vs expert GI-pathologists
The general pathologist assessed 84.8% of the rectosigmoid biop-
sies, endoscopically scored as Mayo 0, as gpHR; in the proximal 
colon biopsies this was 94.1% [Table 2]. For endoscopy score Mayo 
1, the general pathologist assessed 20% [2/10] of the biopsies in the 
rectum and sigmoid as gpHR.
The results of the re-evaluation of the Mayo 0 and 1 biopsies by 
expert GI-pathologists using three histological scores [GS, HGI, RS] 
are depicted in Table 2. To calculate these percentages for all three 
GI-pathologists, we used the sum of all biopsies. The used cut-offs of 
the GS [<0.1, <3.1] were used in concordance with the literature.15
3.4. Inter-observer agreement expert 
GI-pathologists
For all evaluated histological scores, inter-observer concordance was 
higher in sections assessed as Mayo score 1 vs sections assessed as 
Mayo score 0 [Table 3 and Table S4].
3.5. Harpaz [Gupta] index [HGI]
Overall inter-observer concordance in the HGI was substantial 
[0.62]. In primary assessment both as gpHR [0.68] and as gpHI 
[0.63] this was substantial. When the evaluated sections were 
divided according to Mayo score, the inter-observer concordance 
for HGI was moderate for Mayo score 0 [0.55] and substantial for 
Mayo score 1 [0.64] [Table 3].
3.6. Geboes [GS]
Overall inter-observer concordance for the GS with and without 
subscores was almost perfect [0.84 and 0.83]. When the primary 
histological assessment consisted of gpHR the inter-observer con-
cordance was substantial [0.65 and 0.63], and for gpHI there was 
a higher concordance [0.91 and 0.91]. When the evaluated sections 
were distinguished according to the endoscopic Mayo score, the 
inter-observer concordance for GS with subscoring was substantial 
for Mayo score 0 [0.7] and almost perfect for Mayo score 1 [0.93], 
and for GS without subscoring the result was similar [0.68 and 0.92] 
[Table 3].
3.7. Riley score [RS]
Inter-observer concordance was determined for each separate item 
of the RS. The inter-observer concordance for all six items was sub-
stantial to almost perfect [Table S4]. Where the evaluated sections 
were distinguished according to the initial assessment, inter-observer 
concordance was moderate to substantial for all six items in gpHR; 
in gpHI this was almost perfect for five out of six items, with ‘crypt 
architectural irregularities’ as the only outlier with a moderate result. 
When the evaluated items were divided according to Mayo score, 
inter-observer concordance for all items of the RS was fair to sub-
stantial in the case of Mayo score 0 [range 0.35–0.69] and almost 
perfect in five out of six items [range 0.90–0.95] in the case of Mayo 
score 1, with again ‘crypt architectural irregularities’ as an outlier 
with a substantial result [Table S4].
3.8. Global visual score [GVS]
Overall inter-observer concordance in the GVS was substantial 
[0.74]. In those sections primarily assessed as gpHR this was mod-
erate [0.52], whereas in biopsies scored as gpHI this was substantial 
[0.78]. When the evaluated sections were divided according to Mayo 
score, the inter-observer concordance for GVS was moderate in the 
case of Mayo score 0 [0.52] and almost perfect in the case of Mayo 
score 1 [0.92] [Table 3].
3.9. Intra-observer reproducibility histological 
activity scores
Intra-observer reproducibility of reader 1 [IN] and reader 2 [AT] 
in all scores is given in Table 4. Eighteen randomly selected sec-
tions [18/77; 23.4%] with 40 biopsies were blindly reassessed a 
second time by these two expert GI-pathologists. Overall, reader 1 
showed the highest intra-observer reproducibility for the HGI with 
a kappa of 1 and with 100% agreement. For reader 2, the highest 
intra-observer reproducibility [0.86] was for GS without subscor-
ing. With regard to the RS, reader 1 showed 100% agreement for 
Table 1. Demographic variables and details on endoscopy.
Patient characteristics [N = 39]
Age [years] [mean ± SD] 53.4 ± 16.09
Duration of UC [years] [mean ± SD] 23.0 ± 12.9
Male gender [N, %] 23 [59%]
Montreal classification [N, %] E1 6 [15.4%]
E2 12 [30.8%]
E3 21 [53.8%]
Medication [N, %] Mesalamine 28 [71.8 %]
Thiopurines 13 [33.3%]
Corticosteroids 2 [5.1%]
Anti-TNF* 3 [7.7%]
Topical therapy 7 [17.9%]
Endoscopy [N = 43]
Sigmoidoscopy [N, %] 4 [9.3]
Colonoscopy [N, %] 39 [90.7]
Mayo score 1 rectum 9 [20.1]
Mayo score 1 rectosigmoid 10 [23.3%]
Mayo score 1 proximal of splenic 
flexure††
0 [0%]
*One patient used combination thiopurine/infliximab; ††N  =  39 
colonoscopies.
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‘acute inflammatory cell infiltrate, crypt abscesses, mucin depletion 
and surface epithelial integrity’. Reader 2 showed similar results for 
‘crypt abscesses and surface epithelial integrity’.
3.10. Correlations between primary assessment 
[gp], endoscopic Mayo score and histological 
activity scores
Correlation between GS and GVS was substantial[R = 0.73], as was 
that between the RS and the GVS [R = 0.75]. Correlation between 
HGI and GVS was moderate [R = 0.41]. Correlation between the RS 
and the GS was almost perfect [R = 0.86]. Between the RS and the 
HGI, correlation was moderate [R = 0.44], as was that between HGI 
and GS [R = 0.56]. Correlation between the primary assessment and 
the Mayo score was moderate [R = 0.52]. There was no correlation 
between the primary assessment and the GVS [R = −0.04], the HGI 
[R = 0.03], the GS [R = 0.00] and the RS [R = −0.01] as scored by 
the expert GI-pathologists.
There was no correlation between the Mayo score and the GVS 
[R = −0.07], HGI [R = −0.03], GS [R = −0.11] and RS [R = −0.09] as 
scored by the expert GI-pathologists.
4.1. Discussion
This study documents poor concordance between ‘daily practice’ 
histological assessment of HR in UC biopsies by a general patholo-
gist and expert reviews by GI-pathologists. This finding is important 
as our study mirrors daily practice where clinicians are struggling 
with the question whether to alter UC medication and the presence 
of HR may tip the balance in favour of a specific treatment strategy. 
We found strong correlations among expert GI-pathologists between 
the most frequently used histological activity scores for UC [RS and 
GS] and we observed a substantial inter-observer concordance for 
three histological scores [GS, HGI, RS], when re-evaluating UC biop-
sies assessed as HR by a general pathologist. Our study confirmed 
the reported excellent diagnostic properties of the most widely used 
UC histological disease activity indexes24,25 specifically for UC co-
lonic biopsies with MH and limited histological inflammation.
The significant discrepancy we found between histological assess-
ment of UC biopsies in daily practice and expert GI-pathologists 
is probably explained by bias and the need for expertise. The 
GI-pathologists from our research panel were blinded for both clin-
ical and endoscopic data, whereas the initial assessor [in clinical 
practice] had full access to clinical and endoscopy results. It is con-
ceivable that the clinical information available to the general path-
ologist influenced the conclusions of the histological evaluation. 
Secondly, routine histological assessment of IBD mucosal biopsies 
obtained from a colon with MH is complex and probably requires 
expertise that goes beyond routine clinical review. Indeed, some IBD 
studies have shown considerable inter-observer variability between 
pathologists.30,31 Histological inter-observer disagreement is by 
no means rare, nor is it limited to UC. In cancer treatment where 
results from pathology examinations are crucial, central pathology 
reading of biopsies taken in the context of trials is ubiquitous32 
and has made its way into daily oncology care.33–35 This concept 
appears to have traction in IBD trials,36 but is not yet in daily prac-
tice. We applaud the development of novel UC histological activ-
ity indexes37–39 because we need accurate assessment of histological 
activity in both IBD trials and clinical practice. There are two other 
Table 3. Inter-observer concordance among GI-pathologists for 
each histological scoring index.
Index Cronbach’s α 
[95% CI]
Agreement 
[%]
Global Visual Scale [GVS] Overall 0.74 [0.46–0.86] 8.0%
gpHR* 0.52 [0.34–0.62] 9.8%
gpHI** 0.78 [0.12–0.93] 0.0%
Mayo 0† 0.51 [0.37–0.64] 9.2%
Mayo 1†† 0.92 [0.39–0.96] 0.0%
Harpaz Gupta Index [HGI] Overall 0.61 [0.43–0.78] 76.6%
gpHR* 0.51 [0.21–0.66] 82.5%
gpHI** 0.63 [0.31–0.88] 50.0%
Mayo † 0.55 [0.33–0.70] 80.6%
Mayo 1†† 0.64 [0.21–0.914 50.0%
Geboes Score [GS] with 
subscoring
Overall 0.84 [0.68–0.91] 11.7%
gpHR* 0.65 [0.35–0.79] 14.3%
gpHI** 0.91 [0.75–0.97] 0.0%
Mayo 0† 0.70 [0.50–0.81] 13.4%
Mayo 1†† 0.93 [0.76–0.98] 0.0%
Geboes Score [GS] without 
subscoring
Overall 0.83 [0.67–0.90] 35.1%
gpHR* 0.63 [0.34–0.78] 36.5%
gpHI** 0.91 [0.76–0.97] 28.6%
Mayo 0† 0.68 [0.46–0.80] 34.3%
Mayo 1†† 0.92 [0.74–0.99] 40.0%
Riley Score [RS] Overall 0.91 [0.75–0.96] 14.3%
gpHR* 0.73 [0.46–0.86] 15.9%
gpHI** 0.95 [0.75–0.98] 7.1%
Mayo 0† 0.79 [0.58–0.88] 14.9%
Mayo 1†† 0.96 [0.74–0.98] 10.0%
*Biopsies initially evaluated as ‘histological remission’ by general patholo-
gist; **biopsies initially evaluated as ‘histological inflammation’ by general 
pathologist; †biopsies taken from colon segments assessed as endoscopic Mayo 
score 0, ††biopsies taken from colon segments assessed as endoscopic score 
Mayo 1]
Table 2. Histological reassessment of the Mayo 0 and 1 biopsies by expert GI-pathologists – % HR according to general pathologist [gpHR] 
vs expert GI-pathologists.
Mayo score General pathologist Expert GI-pathologists
gpHR* HGI < 1† GS < 0.1† GS < 3.1† RS 0†
Mayo 0 overall 89.6% [60/67] 90.0% [181/201] 29.4% [59/201] 91.0% [183/201] 25.4% [51/201]
Mayo 0 rectosigmoid 84.8% [28/33] 88.9% [88/99] 25.3% [25/99] 88.9% [88/99] 21.2% [21/99]
Mayo 1 rectosigmoid 20% [2/10] 70.0% [21/30] 16.7% [5/30] 63.3% [19/30] 20.0% [6/30]
Mayo 0 proximal colon 94.1% [32/34] 91.2% [93/102] 33.3% [34/102] 93.1% [95/102] 29.4% [30/102]
HGI = Harpaz Gupta Index; GS = Geboes score; RS = Riley score; *gpHR = biopsies initially evaluated as ‘histological remission’ by general pathologist; †com-
mon cut-offs for histological remission.
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histological indexes for UC that merit discussion. Both the Nancy 
Index and the Robarts Histopathology Index [RHI] have shown 
good reproducibility, reliability and responsiveness, and under-
went the most extensive validation of all existing histological activ-
ity indexes for UC.37,38,40 The validation process for both indexes 
has been performed by expert pathologists, and both mainly use 
key items that are also present in existing scores such as GS, RS, 
HGI, Gramlich and GVS. These key items had high intra- and inter-
observer agreement and were subsequently included in the Nancy 
Index and RHI. Given the overlap of the included histological items 
[such as ulceration and acute inflammatory cell infiltrate], inclusion 
of either the Nancy Index or the RHI in our study would not change 
our key message. The real matter at stake, based on current study 
results, is the gap between the initial and expert histological assess-
ment. Efforts to overcome this gap should be directed at dedicated 
learning pathways and/or central reading facilities. The Nancy 
Index might gain a future central role in these learning pathways 
because it is simple and easy to use. We found higher inter-observer 
concordance between expert GI-pathologists in the biopsies that 
were assessed by a general pathologist as histological inflamed 
compared to HR for all three histological activity scores. Similar 
results were found after categorization into endoscopic Mayo score 
0 and 1, in favour of the Mayo 1 group. Both findings suggest 
that is it more complicated, even for specialized GI-pathologists, 
to reach an agreement in cases of minor histological inflammation. 
This assumption concurs with a study from the 1990s that investi-
gated the reliability of the interpretation of IBD colonic biopsies by 
specialized GI-pathologists. True normal biopsies were frequently 
assessed as ‘possible’ or ‘likely’ ‘non-specific inflammation’ without 
agreement on this item.30
In our study we found no correlation between the endoscopic 
Mayo score and any histological scores. In the case of Mayo 0 at 
endoscopy, we found histological activity in 20% [GS > 3.1] to 
80% of cases [GS > 0.1] depending on the definition of HR used. 
In line with these results, a previous study described histological in-
flammation [GS ≥ 3.1] in 40% of cases with MH at endoscopy.41 
Unfortunately there is no unified definition of HR and the cut-off 
level of histological activity that is clinically relevant is still of de-
bate.15 Our study has several strengths and clinical implications. To 
mimic daily practice with regard to HR decision-making, we only 
used biopsies reported as endoscopic MH, and we involved expert 
GI-pathologists from both academic and non-academic hospitals. 
For these histology analyses, we used blinded readers, which reduces 
the potential bias of taking the clinical condition of the patient into 
consideration. Most importantly, the described discrepancy between 
histological assessment of UC biopsies in daily practice and reassess-
ment by dedicated GI-pathologists may have important implications 
in daily practice. Medical decision-making may increasingly depend 
on histological remission, and therefore it is important to realize 
and act upon this finding. There are some limitations of this study. 
First, the retrospective design of the study harbours the risk of bias. 
Secondly, the consensus meeting between GI-pathologists, before 
initiation of the study, may have caused bias by achieving a better 
inter-observer agreement. Third, we did not use central reading42 for 
the endoscopic Mayo score, but used the Mayo score as reported by 
the endoscopist. In addition, the Mayo score has a variable inter-
observer concordance,42–44 although this is likely to have little impact 
on the scope of this article.
In summary, the use of existing histological activity indexes eval-
uating UC colonic biopsies that were initially assessed as HR resulted 
in substantial inter-observer concordance. Of alarm is the observa-
tion that there was no correlation between the primary assessment 
of UC biopsies by the general pathologist and the reassessment by 
blinded expert GI-pathologists. This may have important implica-
tions for the selection process of a unified histological disease activity 
score in UC, and for the implementation of HR as a UC treatment 
target in daily practice.
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Table 4. Intra-observer reproducibility for each histological scoring index and separate items of the Riley score.
Index Reader 1 [IN] Reader 2 [AT] Reader 1 [IN] Reader 2 [AT]
Cronbach’s α [95% CI] Cronbach’s α [95% CI] Agreement [%] Agreement [%]
GVS 0.34 [-0.78–0.75] 0.85 [0.61–0.95] 55.6% 50%
HGI 0.00 [0.00–1.00] 0.61 [-0.05–0.90] 94.4% 88.9%
GS with subscoring 0.73 [0.27–0.90] 0.86 [0.63–0.95] 72.2% 55.6%
GS without subscoring 0.61 [-0.05–0.85] 0.86 [0.64–0.95] 88.9% 66.7%
RS 0.79 [0.44–0.92] 0.82[0.51–0.93] 61.1% 44.4%
RS item
Acute inflammatory cell infiltrate 0.00 [0.00–1.00] 0.93 [0.82–0.98] 88.9% 94.4%
Crypt abcesses 0.00 [0.00–1.00] 1.00 [0.00–1.00] 94.4% 100%
Mucin depletion 0.00 [0.00–1.00] -0.18 [-0.44–1] 77.8% 83.3%
Surface epithelial integrity 1.00 [0.00–1.00] 0.00 [0.00–1.00] 100% 94.4%
Chronic inflammatory cell infiltrate 0.79 [0.44–0.92] 0.78 [0.41–0.92] 94.4% 72.2%
Crypt architectural irregularities 0.93 [0.80–0.97] 0.79 [0.44–0.92] 72.2% 72.2%
GVS = Global Visual Scale; HGI = Harpaz Gupta Index; GS = Geboes score; RS = Riley score.
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